[Federal Register: April 2, 2003 (Volume 68, Number 63)]
[Notices]               
[Page 16089-16090]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02ap03-132]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on January 14, 2003, 
Mallinckrodt, Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 
63147, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of the 
basic classes of controlled substance listed below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Codeine-N-oxide (9053).....................  I
Diprenorphine (9058).......................  II

[[Page 16090]]


Etorphine HCl (9059).......................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9160)...........................  II
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
Difenoxin (9168)...........................  I
Diphenoxylate (9170).......................  II
Benzoylecgonine (9180).....................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Heroin (9200)..............................  I
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Methadone intermediate (9254)..............  II
Metopon (9260).............................  II
Dextropropoxyphene, bulk (9273)............  II
Morphine (9300)............................  II
Morphine-N-oxide (9307)....................  I
Nicomorphine (9312)........................  I
Normorphine (9313).........................  I
Thebaine (9333)............................  II
Opium extracts (9610)......................  II
Opium fluid extract (9620).................  II
Norlevorphanol (9634)......................  I
Opium tincture (9630)......................  II
Opium, powdered (9639).....................  II
Opium, granulated (9640)...................  II
Levo-alphacetylmethadol (9648).............  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
Tetrahydrocannabinols (7370)...............  I
------------------------------------------------------------------------

    The firm plans to manufacture the controlled substances as 
analytical reference standards to be used internally and for sale to 
other companies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Drug Operations Section, Domestic Drug 
Unit (ODOD) and must be filed no later than 60 days from publication.

    Dated: March 14, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-7826 Filed 4-1-03; 8:45 am]

BILLING CODE 4410-09-M